The WACC of Suven Life Sciences Ltd (SUVEN.NS) is 9.9%.
| Range | Selected | |
| Cost of equity | 12.20% - 16.70% | 14.45% |
| Tax rate | 30.00% - 30.00% | 30.00% |
| Cost of debt | 7.00% - 8.30% | 7.65% |
| WACC | 8.5% - 11.2% | 9.9% |
| Category | Low | High |
| Long-term bond rate | 6.9% | 7.4% |
| Equity market risk premium | 8.3% | 9.3% |
| Adjusted beta | 0.64 | 0.95 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 12.20% | 16.70% |
| Tax rate | 30.00% | 30.00% |
| Debt/Equity ratio | 1 | 1 |
| Cost of debt | 7.00% | 8.30% |
| After-tax WACC | 8.5% | 11.2% |
| Selected WACC | 9.9% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for SUVEN.NS:
cost_of_equity (14.45%) = risk_free_rate (7.15%) + equity_risk_premium (8.80%) * adjusted_beta (0.64) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.